Filing Overview
This Form 6-K covers the month of August 2023 and was filed on August 17, 2023. The filing identifies the registrant as I-MAB, a foreign private issuer headquartered in Shanghai, China, with Commission File Number 001-39173. The provided filing does not identify Novabridge Biosciences.
Financial Metrics
The filing cover page does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes
No material financial or operational changes are described in the provided text. The filing incorporates a press release as Exhibit 99.1, but the press release content is not included.
Guidance, Risks, and Other Items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are provided in the available filing text.
Investor Verification Items
- Verify that I-MAB is the intended registrant, since the request identifies Novabridge Biosciences.
- Review Exhibit 99.1, the referenced press release, for the substantive disclosure.
- Confirm the applicable reporting period and any financial or operational information in the complete Form 6-K filing.
- Note that the filing is made under Form 20-F reporting status.